We begin with a decision-theoretic investigation into confidence sets that minimize expected volume at a given parameter value. Such sets are constructed by inverting a family of uniformly most powerful tests, and hence they also enjoy the optimality property of being uniformly most accurate. In addition, these sets possess Bayesian optimal volume properties and represent the first case (to our knowledge) of a frequentist 1 -α confidence set that possesses a Bayesian optimality property. The hypothesis testing problem that generates these sets is similar to that encountered in bioequivalence testing. Our sets are optimal for testing bioequivalence in certain settings; in the case of the normal distribution, the optimal set is a curve known as the limaçon of Pascal. We illustrate the use of these curves with a biopharmaceutical example.
Introduction
The construction of good set estimates of a parameter, both frequentist and Bayesian, has long been a goal of statisticians. The formalization of "good" set estimates is usually in terms of some measure of the size of the set, often taken to be the volume of the set. Alternatively, the size of the set can be measured by its probability of false coverage. Thus, if C(x) is a set estimate of a parameter 8, P 8 (8 E C(X)) is the probability of true coverage, while P 8 (8' E C(X) ), 8 =f. 8', is the probability of false coverage.
The false coverage of C(x) can be related to its volume through the Ghosh-Pratt identity (Ghosh 1961; Pratt 1961 ), (1.1) but this has rarely been used in establishing volume optimality. An exception is the work of Cohen and Strawderman (1973) . Equation (1.1) illustrates that possession of an optimal expected volume is a somewhat stronger property than possessing optimal false coverage probabilities, since expected volume can be regarded as a sum over all false coverages. Since admissibility with respect to expected volume implies admissibility with respect to false coverage probability, a procedure with optimal expected volume will have attractive false coverage properties. However, the converse is not true. As domination of false coverage probabilities ties directly into testing theory, where much is known about optimality, we find many cases where set estimates with optimal false coverage properties do not have optimal volume properties. For example, the usual multivariate normal confidence set cannot be uniformly dominated in false coverage, but it can be dominated in volume (see Hwang 1983 or Shinozaki (1989) .
There is, however, an instance in which false coverage and volume are equivalent. That is when there is interest in producing a procedure that is optimal at some point in the parameter space.
Thus, if there is interest in minimizing volume at a parameter value 8=8*, then this can be accomplished by minimizing all of the false coverages at 8=8*. Doing so brings the construction of optimal volume confidence sets back into a Neyman-Pearson testing set-up.
At first it may seem surprising that one can construct a confidence set that has optimal size at 8=8* while maintaining a nominal coverage probability for all parameter values. However, this problem is a version of what was solved by Sterne (1954) in the binomial case (see also Crow 1956 ).
For X"" binomial (n, p), Sterne proposed to construct a confidence set for p by inverting acceptance regions composed of the fewest X values necessary to have a rejection region with prespecified size a.
He noted that such a set minimized the sum of the n+ 1 lengths. It turns out that such a construction, which is a Neyman-Pearson-type construction, will yield sets of minimum volume at 0=0*. process of minimizing the expected volume at a value 0=0* can also be used to minimize a Bayesian expected volume, that is, an expected volume integrated over a prior distribution. Thus, our construction gives a frequentist confidence set (one that maintains a nominal coverage probability) that optimizes a Bayesian measure of volume.
In Section 2 we formalize the decision-theoretic problem, and establish an optimality theorem in the frequentist setting. We also consider the normal case in detail, where the lim~on of Pascal appears. Section 3 connects these results to the Bayesian formulation, and shows how to construct optimal frequentist/Bayes intervals. Section 4 addresses the unknown variance case, and we see that the known variance optimality results can be generalized to this case. Lastly, Section 5 discusses the connections to the problem of bioequivalence testing. We also present an example showing how bioequivalence confidence sets based on the lim~on can provide sharper inferences.
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The Frequentist Interpretation

A General Formulation
Let X have continuous density (for convenience) f( ·10) with respect to Lebesque measure. Given that we observe X = x, we set up a confidence set for 0. This set, C{x), may be a randomized set, and has inclusion probability (2.1) That is, cp(O lx) is the probability of including the value 0 in the set when x is observed. For nonrandomized sets cp(O lx) = 1(0 E C(x)), the indicator function of the set C{x). {Randomized rules are only included for completeness of the theory, as they should never be recommended in practical applications.)
The volume of the set C{x), vol ( C{x)), with respect to Lebesque measure, is given by with expected volume
In addition to calculating (2.3) as a measure of size, it i.s usual to calculate the frequentist coverage probability of the set C(x), that is P 0 (oec(x))= Jcp(Oix)f(xiO)dx.
$ (2.4)
A standard frequentist requirement is to have this coverage probability greater than some nominal level, say 1-a, for all values of 0. Subject to that constraint, we seek to minimize the expected volume of C(x) at a selected value of 0. Without loss of generality we take 0=0 and, to avoid trivial pathologies, 0 < a < 1. Thus, the problem of interest becomes:
Over all confidence sets C(x), minimize E 0 vol( C(X)) subject to
(2.5)
Before stating and proving a formal theorem, note that the specifying of 0=0 in the volume requirement, which puts a particular importance on this value, makes one think of a hypothesis testing formulation. However, the formulation of a hypothesis test that is equivalent to (2.5) is not entirely straightforward, for the specified value 0=0 is not part of the null hypothesis, but of the alternative hypothesis.
Consider testing for which E 00 (.,p 00 (X)) =a. As in (2.1), define confidence sets C* with
It is this confidence set that solves the problem in (2.5). Note that in the usual non-randomized case the confidence set is
Theorem 2.1: Let X -f( ·10), and let ~*(Oix) be given by (2.7). The confidence set C*(x) minimizes the expected volume at 0 = 0 among all1-a confidence sets.
Proof: The proof is based on the Ghosh-Pratt identity (Ghosh 1961; Pratt 1961) , and can be found in Pratt's paper (along with the one-dimensional normal example). We have for any confidence set
where <p( (J I x) is the probability that () is included in C(x) when x is observed. Interchanging the order of integration gives
(2.9)
eg; e
The integrand in (2.9) is the probability of false coverage, which is minimized, subject to (2.5), by the uniformly most accurate set C*(x), and in turn produces the minimum expected volume. 0
It should be noted that any weighted volume measure can be used and Theorem 2.1 would remain valid. That is, if we measure the size of a set C(x) by
where v( ·) > 0 is some weight function, then C*(x) of (2.8) minimizes (2.10) over all 1-a confidence sets.
The Normal Case
To better understand the behavior of C*(x), we look at it more closely in the normal case. If X has a p-variate normal distribution, X"' N p(O, I), then for the hypothesis test (2.6) we would reject where k*(0 0 ) is chosen to give the test size a. Thus, the confidence set is C*(x) = {0 :
To evaluate the form of k*(O), we use the fact that W = O'X/1 0 I""' n(l (}I, 1), regardless of the dimension of X. Then, for (} =P 0 the coverage probability is
for k*(O) = I(} I (lOl-a), where <I>(·) is the standard normal cdf. Choosing a= <I>-1 (1-a) yields a 1-a confidence interval.
To better understand the shape of C*(x), write x'O = I x 1101 cos /3, where cos f3 = x'O /I x 1101, and f3 is the angle between x and 0. Then, in the normal case the optimal confidence set is C*(x) = {0: 101 :5a+ lxlcos/3}.
(2.10)
The boundary of this set is the main lobe of a curve known as the lim~on of Pascal, a curve that is often used in calculus courses to illustrate polar coordinate techniques. (The lim~on was actually studied by Etienne Pascal, the father of the famous Blaise Pascal, see Archibald 1900) . The lim~n is shown in Figure 1 , and the confidence set (2.10) is graphed in Figure 3 for various values of x when p = 2. It is interesting to note that when x = 0 the set is a sphere, but as x moves away from zero there is a distinct nonconvexity to the set. (The lim~on is actually a generalization of the cardiod, a "heart-shaped" polar curve.) As x tends toward infinity the lim~on becomes more like a sphere. In higher dimensions, the lim~on shape is retained. If we graph a higher dimensional lim~on by identifying the x-axis with the data x, and using f3 as the angle between 0 and x, equation
(2.10) will resemble the lim~on in Figure 1 . The remainder of the set is then generated by rotating the lim~on about the x-axis.
Notice that C*(x) has coverage probability <J>(a) regardless of the dimension of the problem. In one dimension some further simplifications can be made.
Here we have W I X I sgn( OX) "" n( I 0 I, 1 ), and C*(x) = { 8 : I xI sgn(Ox) ~lOl-a}= { 0 : min(O, x-a) :5 () :5 max (0, x +a)} .
(2.11)
The 95% confidence interval has a = 1.645, and is equal to x ± 1.645 for small I xI· The usual twosided 95% confidence interval is x ± 1.96. Thus, C*(x) is narrower than the usual interval for small values of x, but wider for larger values. C*(x) does have an interesting property, however, in that it falls on one side of zero for smaller values of I xI than the usual interval, thus allowing an experimenter more power in making formal conclusions about the sign of 0. with the usual one-dimensional interval.
As mentioned before, the one-dimensional C*(x) was first derived by Pratt (1961) , who also discussed the connection with the Sterne-Crow intervals for a binomial success probability {Crow 1956). However, the interval (2.11) has another history, emerging from the work of Hsu {1981, 1984 .
He derived the interval in the context of a multiple decision problem, where one is interested in confidence intervals for the distance from the best mean. A discussion of C*(x), and demonstration of some properties, can be found in Exercise 9.31 of Casella and Berger, 1990 .
The expected volume, at 0 = 0, can also be evaluated for C*(x).
{0: 10 I :5 w+a}, where W "'n( 10 I, 1), we have
e {x: j; 0
where the last equality follows from the fact that for X"' N(O, 1), X'0/101 "'N(O, 1) for any nonzero 0. If we then apply a polar transformation we have
Note that 'TrP/ 2 / f(p/2 + 1) is the volume of a p-sphere of radius 1, so the pth root of the integral in (2.13) is, effectively, the radius of the set. For p = 1 we can write but for other values of p the integral is harder to evaluate. Table 1 gives some values of the pth root of Eo vol( C*(x)) and, for comparison, the corresponding values for C 0 (x), the usual confidence sphere. Table 1 Effective volume (pth root of expected volume) of C*(x) and C 0 (x), Of course, for 0 ::/= 0, Eo vol(C*(x)) will grow larger than Eo vol(C 0 (x)) (which is constant in 0), the discrepancy increasing as I 0 I increases. We illustrate this with Figure 3 , which compares realized values of the two sets for a variety of x values. Note that the different graphs have different scales, and the value of x is the center of the sphere. We now seek to minimize (3.1), a Bayesian measure, among all sets C(x) that satisfy the frequentist coverage probability constraint, P 0 (o E C(x)) ~ 1-a.
In Section 2, the minimizing set was constructed from testing H 0 : (} = 0 0 vs HI : () = 0 or, equivalently, H 0 : X "" f(x I 0 0 ) vs. HI: X "" f(x I 0). In the Bayesian formulation, the minimizing set is constructed from the test
where m11"(x) = J e f(x I 0) 11"(0) dO. The confidence set is, therefore, given by
We have the following theorem 
where (r 2 +1 I r 2 f k*(O) is the upper a critical point of a noncentral chi-squared distribution with noncentrality parameter I(} 1 2 jr 2 . It can be shown that as r 2 -+ 0 this set reduces to C*(x) of the previous section and, as r 2 -+ oo, this set approaches the usual sphere c 0 (x).
Generalizations to the Case of Unknown Variance
The set C*(x) of (2.8) is optimal in cases where there are no nuisance parameters, and the normal examples of Section 2.2 all reflect this. Of course, the more practical problems usually involve nuisance parameters, and we now consider that case. We restrict our discussion to the normal distribution with unknown mean and variance.
With a sample x 1 , · ··, Xn from n(O, u2) with both parameters unknown, there are two ways of generalizing the procedure of Section 2. The first, which is perhaps the more obvious way, is to test the hypotheses (4.1)
Using a standard Student's t test, this leads to intervals of the form
where t a n-1 is the upper a cutoff from Student's t distribution with n-1 degrees of freedom. It is ' straightforward to verify that Ct(x, s) is a 1-a confidence interval, although it doesn't enjoy the same optimality properties as the interval (2.8). This interval was also considered by Hsu, Hwang, Liu, and Ruberg (1993), although they did not investigate its optimality. We detail its exact optimality below.
For this problem it is natural to consider only confidence 6ets related to the usual (scaleinvariant) t-tests of H 0 • This means that the inclusion probabilities of the confidence set must be of the form (4.3)
Note that the intervals of ( 4.2) have this form.
A second, perhaps less obvious way of generalizing Section 2.2 is to modify the hypotheses of where ' 7o is a fixed constant. On defining '1 = Oju, we see that we are reduced to considering a oneparameter problem. In practical terms, the hypotheses ( 4.4) are also quite interesting, because the "signal-to-noise ratio" '1 = Oju is often of interest. We will see that (4.4) leads to a confidence interval for TJ that is different from any confidence sets for 0, in particular (4.2).
For the hypotheses ( 4.4) a reasonable invariant procedure will be of the form where f(x/s I TJ) is the noncentral t distribution with noncentrality parameter 1J and n -1 degrees of freedom. The function k( 1J) is chosen so that ct is a 1-a confidence set, c;hat is, so that the -11-corresponding tests in ( 4.4) have level a. Figure 4 shows a plot of these intervals, along with the normal (u known) intervals. It is interesting to note that the resulting boundaries are curved, in contrast to the straight line boundaries in the known u case.
Construction of the intervals given by ( 4.6) is actually quite straightforward, exploiting monotonicity properties of both the density and distribution function of the noncentral t. Note first that since f( t I q) has monotone likelihood ratio, the acceptance region of the test ( 4.4), that is H 0 : '7 vs. H 1 : '7 = 0, is given by Now the distribution function, F(t I q), is decreasing in q, so an a-level test is constructed by solving F(tl k} 1 (t)) =a: and F(tl k2 1 (t)) = 1-a:, and setting '7u(t) = k} 1 (t) and '7L(t) = k2 1 (t) yields
Note that tdis construction holds, in general, as long as the density satisfies suitable monotonicity conditions. It aiso follows that the confidence interval ( '7 £< t ), '1u( t)) is a 1-2a: interval.
For both the set-ups leading to (4.1) and {4.4) we can establish optimality properties of the resulting confidence sets.
Theorem 4.1: Among all 1-a: confidence sets for ()of the form (4.3), the intervals (4.2) minimize Eo,u ( vol ( C( X, S))) for every u 2 > 0.
Proof: As in the proof of Theorem 2.1, use the Ghosh-Pratt identity to write 00 Eo,u ( vol(C(X, S))) = J Po,u(9eC(X, S))d9.
-oo
Among all 1-a: confidence sets of the form (4.4) the integrand is minimized for each() by the Ct of ( 4.2), because these intervals correspond to most powerful level a invariant tests of the hypotheses (4.1). D Theorem 4.2: Among all invariant 1-a: confidence sets for fJ = () / u, the intervals ( 4.6) minimize Eo,u ( vol(C(X, s>)).
Proof: This follows from Theorem 2.1 upon taking into account the monotone likelihood ratio property of the noncentral t distribution. D
Without the restriction (4.3) the confidence intervals (4.2) are not optimal. In fact, they are not even admissible, since it is possible to construct 1-a confidence intervals with smaller expected length for every () = 0, u > 0. This is possible because the results of Brown and Sackrowitz (1984) enables construction of level a: tests, fPBs(9IX, S) of (4.1), whose power strictly dominates that of the one-sided t-tests leading to (4.2) Consequently, this family of critical functions leads to intervals which dominate those of (4.2), as can be seen by applying the Ghosh-Pratt identity as in the proof of Theorem 4.1.
For each 6, tT the (1-a) confidence intervals constructed above have coverage exceeding 1-a, since the tests of Brown and Sackrowitz have size smaller than a. But inf {P6,u(thCBs(X, 5))16, u} = 1-a. We do not know whether the intervals CBs are admissible.
Brown and Sackrowitz show their tests are admissible for testing Ho: 6 = 6 0 , tT > 0 vs. either HI : 6 > 0 if 6 0 < 0 or HI :6 < 0 if 6 0 > 0; however, they do not prove admissibility for H 0 , HI of (4.1) as would be needed to establish admissibility of CBS· By contrast, the intervals in Theorem 4.2 are admissible for pfu. This is because the tests involved are UMP invariant and hence are Bayes among invariant tests. The invariance group here is the group of scale tramsformations and, applying the results of Brown and Fox (1974) , a procedure that is Bayes among invariant procedures is admissible. Admissibility of the tests implies admissibility of the confidence sets.
Generalizations to higher dimensions should also be of interest. Presumably, the lim~on does not appear here because the relevant distributions are multivariate t rather than multivariate normal as in Section 3.
ConnectioDS with Bioequivalence
The intervals discussed here, particularly the form ( 4.2), have seen practical use in bioequivalence testing. This brings us to the interesting connection between bioequivalence and the lim~n of Pascal. Note that what is typically the "null hypothesis" is placed in the alternative, as this is the research hypothesis of interest. One of the first researchers to formulate the bioequivalence problem in this was Anderson and Hauck (1983) . (See also Anderson 1984, 1992 . The lat~er is a review paper.)
A technique of carrying out a test of (5.1), as required by the FDA {FDA, 1992), is to perform two one-sided tests, as described by Schuirmann {1987), for example. This procedure establishes bioequivalence of l't and p 2 , at level a, if both of the following two one-sided test of (J = p 1 -1'2 reject the null hypothesis at level a:
i) H 0 : 9 ~ -6 vs.
vs.
It ·is interesting to note that (5.2) is a case of an intersection-union test, as developed by Berger {1982). As the overall hypothesis of interest, that -6 ~ (J ~ 6 is an intersection of the two other hypotheses, individual a-level tests lead to an overall a-level test for (5.1). Additionally, referring to the discussion following (4.6), it turDS out that Schuirmann's procedure leads to basing the conclusion on the non-truncated confidence interval, which seems to have confidence 1-2cr, the wrong level. The a-level is actually correct, however, the intervals are wider than necessary.
Although interest has usually centered around the testing problem in (5.1), there is also considerable interest (and benefit) in constructing confidence intervals for p 2 -p 1 • Given a 1-a confidence interval C(x) for p 2 -p 1 , an a-level test of (5.1) can be conducted by rejecting H 0 whenever C{x) C (-6, 6) , as proposed by Westlake (1972 Westlake ( , 1976 . (Notice that this use of confidence sets as tests is reversed from the usual use. The values of p 2 -p 1 in the interval ( -6, 6) are those for which bioequivalence will be declared, which is the alternative hypothesis.)
The confidence set approach to bioequivalence testing has an added benefit in that the constant 6 does not have to be prespecified. Indeed, for a given 1-a bioequivalence confidence set C(x), and any set ~. we could conclude H 1 : p. There are other formulations of the bioequivalence hypothesis, formulations that lead to alternate tests and confidence intervals. For example, one could specify 6 of (5.1) in terms of the variance 0'; that is, two procedures are declared bioequivalent if their mean difference is no more than a specified proportion of their variance. Of course, this formulation leads directly to the hypotheses specified in ( 4.4), and to the noncentral t-based intervals of ( 4.6). Although this formulation of the bioequivalence problem has been used, the optimal procedure of ( 4.6) has not been employed.
Lastly, the bioequivalence problem can be a multivariate one, where the full advantage of the lim~on can be enjoyed. To test the bioequivalence of p formulations, one might specify a set a (possibly a hyperrectangle) in which the differences must lie. By constructing a lim~on confidence set, overall bioequivalence can be examined. Bioequivalence would be concluded if the lim~on confidence set falls entirely within a.
We illustrate this last situation with data from Ruberg and Stegeman (1991) , on equivalence of batch degradation slopes. (We make a simplifying (but seemingly reasonable) assumption about the batch variation. For an alternative analysis, based on multiple comprison techniques, see Ruberg and Hsu (1992) .) Each of p = 6 batch slopes, {3 1 , • · ·, {3 6 , is used to estimate the shelf-life of a product.
Here we look at the bioequivalence of the differences i =2,···,p.
The data are assumed to be independent normal with known variance; that is, we observe to the form of (2.10) with the transformation '1 = r;2(J, i) = r;29. The set (5.2) is somewhat of an elliptical lim~on, and is shown in Figure 5 . We show two-dimensional projections of the fivedimensional set, which gives the smallest a for which bioequivalence will be declared. ::3.. 
